Furthermore, clinical trials undertaken with prostate cancer patients who are carriers of a mutant PALB2 have demonstrated a positive response to Olaparib treatments, particularly for patients with resistance to treatment [33,48]. Here, PALB2 is linked to prostate carcinoma.